Inno-Gene SA
WSE:IGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Inno-Gene SA
Cash & Cash Equivalents
Inno-Gene SA
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Inno-Gene SA
WSE:IGN
|
Cash & Cash Equivalents
zł294k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Cash & Cash Equivalents
zł507.6k
|
CAGR 3-Years
194%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Cash & Cash Equivalents
zł176.5m
|
CAGR 3-Years
30%
|
CAGR 5-Years
15%
|
CAGR 10-Years
41%
|
|
|
S
|
Selvita SA
WSE:SLV
|
Cash & Cash Equivalents
zł14.4m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Inno-Gene SA
Glance View
Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
See Also
What is Inno-Gene SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
294k
PLN
Based on the financial report for Jun 30, 2024, Inno-Gene SA's Cash & Cash Equivalents amounts to 294k PLN.
What is Inno-Gene SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-5%
Over the last year, the Cash & Cash Equivalents growth was 9 700%.
You don't have any saved screeners yet
